Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Eliyahu Sharon Kalif is EVP, Chief Financial Officer at Teva Pharmaceutical Industries. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 16, 2025, each linked to the official Form 4.
EVP, Chief Financial Officer
Disclosures on record
2
Companies involved
1
As of the latest filing on , Eliyahu Sharon Kalif reported holding 403,288 shares of Teva Pharmaceutical Industries (TEVA), worth about $17.9M at the last close of $45 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 403,288 | 403K direct | $45 | $17.9M | Jun 12, 2025 |
Is this Eliyahu Sharon Kalif’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Teva Pharmaceutical IndustriesTEVA
2 disclosures · Mar 2025 – Jun 2025 · 2 sold
Jun 12, 2025Sold~$952Kdisclosed Jun 16
DetailsOfficial recordFeb 28, 2025Sold~$903Kdisclosed Mar 4
DetailsOfficial recordOn the latest SEC Form 4, dated Jun 12, 2025, Eliyahu Sharon Kalif reported holding 403,288 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $17.9M. This is the stake disclosed in filings, not a net worth.
Eliyahu Sharon Kalif has no open-market purchase on record since 2022. Sales in each of the last 4 years.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2025.
Teva Pharmaceutical Industries (TEVA), from 2022 to 2025: 0 purchases and 5 sales.
Eliyahu Sharon Kalif has no open-market purchase on record since 2022. Sales in each of the last 4 years.
Eliyahu Sharon Kalif reported 0 open-market purchases and 5 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $1.86M2×2 trades |
| 2024 | — | $1.05M1×1 trade |
| 2023 | — | $342K1×1 trade |
| 2022 |
$559K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Eliyahu Sharon Kalif reported 0 open-market purchases and 5 sales here, 2022 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
